GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

  • End date
    Oct 19, 2022
  • participants needed
  • sponsor
    Ionis Pharmaceuticals, Inc.
Updated on 19 July 2021
geographic atrophy
corrected visual acuity
fundus autofluorescence imaging
pupillary dilation
age-related macular degeneration
macular degeneration
fundus autofluorescence


The purpose of the study is to evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).


The study will assess the rate of change of the area of GA secondary to AMD by measuring FAF in up to 330 participants with GA due to AMD being treated with IONIS-FB-LRx. The study is a Phase 2, double-masked, randomized, stratified, placebo-controlled study conducted at multiple centers. It is an adaptive design in which three dose levels will be evaluated in a subset of patients (Stage 1) and, following an interim analysis, the number of patients in two of the dose cohorts will be expanded (Stage 2).

Condition Dry Macular Degeneration, age-related macular degeneration, Maculopathy, Macular Degeneration, Geographic Atrophy
Treatment Placebo, IONIS-FB-Lrx
Clinical Study IdentifierNCT03815825
SponsorIonis Pharmaceuticals, Inc.
Last Modified on19 July 2021


Yes No Not Sure

Inclusion Criteria

Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal
Vaccination against Neisseria meningitidis and Streptococcus pneumoniae received at least 2 weeks prior to first dose of investigational product
Well-demarcated geographic atrophy (GA) due to AMD
Best-corrected visual acuity (BCVA) letter score of 35 letters (approx. 20/200 Snellen equivalent) or better on the ETDRS chart
Must have clear ocular media and adequate pupillary dilation in the study eye to permit high-quality fundus imaging

Exclusion Criteria

Clinically-significant abnormalities in medical history
A lack of full recovery from any infection for at least 14 days prior to the Study Drug administration
Chronic treatment with steroids, including topically or intravitreally administered
History or presence of diabetic retinopathy or diabetic macular edema (DME)
History or presence of a disease other than AMD that could affect vision or safety assessments
Prior treatment with another investigational drug, biological agent, or device
Other protocol-specified inclusion/exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note